Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the microbiological cure rate of doripenem in the treatment of patients with complicated urinary tract infection or pyelonephritis. The study will also characterize the safety and tolerability of treatment with doripenem in patients with complicated urinary tract infection or pyelonephritis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Collaborator: Peninsula Pharmaceuticals, Inc.
• Treatments: Doripenem

Criteria

Inclusion Criteria:

• Diagnosis of complicated lower urinary tract infection or pyelonephritis

Exclusion Criteria:

• Women who are pregnant, nursing or of child-bearing potential and not using a medically accepted, effective method of birth control

• History of moderate or severe hypersensitivity reactions to antibiotic medications